For example, probes targeting the type 2 vesicular monoamine transporter (VMAT2)11–13 or the glucagon-like peptide-1 receptor (GLP-1R)14,15 demonstrated reduced PET/SPECT signals in T1D patients compared to the healthy control. This evidence concerns the gene GLP1R and type 1 diabetes mellitus.